Migraine And Headache

Migraine Associated With Increased Risk for Postsurgical 30-Day Hospital Readmission for Pain

Migraine Associated With Increased Risk for Postsurgical 30-Day Hospital Readmission for Pain

Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.

Migraine Pain Location May Not Have Clinical Implications

Migraine Pain Location May Not Have Clinical Implications

By

The location of migraine pain may not be associated with psychiatric distress, emergency department visits, or healthcare use.

Butalbital/APAP Capsules Launched for Complex Tension Headache

Butalbital/APAP Capsules Launched for Complex Tension Headache

By

Mayne Pharma Group announced the availability of Butalbital/Acetaminophen 50mg/300mg Capsules indicated for the relief of the symptom of complex tension headache.

New Device Available for Patients With Episodic Cluster Headache, Migraine

New Device Available for Patients With Episodic Cluster Headache, Migraine

By

GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.

Chronic Migraine and Medication Overuse Headache Linked to Stress

Chronic Migraine and Medication Overuse Headache Linked to Stress

By

The investigators sought to evaluate whether early-life traumatic experiences, stressful life events, and alexithymia are associated with chronic migraine and medication overuse headache.

Risk of Cochlear Disorders Up With History of Migraine

Risk of Cochlear Disorders Up With History of Migraine

The risk of cochlear disorders, especially tinnitus, is increased among patients with a history of migraine.

Efficacy of Mindfulness-Based Therapies Challenged in Chronic Headache

Efficacy of Mindfulness-Based Therapies Challenged in Chronic Headache

By

The investigators sought to evaluate the efficacy and safety of mindfulness-based stress reduction and mindfulness-based cognitive therapy in the reduction of the symptoms associated with chronic headaches.

Two-Thirds of Parents Report Their Child Has Had Headache

Two-Thirds of Parents Report Their Child Has Had Headache

Two-thirds of parents report that their child has had a headache not related to a fall or head injury.

White Matter Hyperintensities Demonstrate Specific Spatiotemporal Evolution in Reversible Cerebral Vasoconstriction Syndrome

White Matter Hyperintensities Demonstrate Specific Spatiotemporal Evolution in Reversible Cerebral Vasoconstriction Syndrome

By

The characteristics of white matter hyperintensities were assessed to provide information on the underlying mechanisms of these lesions in individuals with reversible cerebral vasoconstriction syndrome.

Co-Prescription of Opioids and Antidepressants Prevalent in Migraine

Co-Prescription of Opioids and Antidepressants Prevalent in Migraine

By

Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.

Fremanezumab Chronic Cluster Headache Study Discontinued

Fremanezumab Chronic Cluster Headache Study Discontinued

By

Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.

Levetiracetam Effective as Episodic Migraine Prophylactic

Levetiracetam Effective as Episodic Migraine Prophylactic

By

The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.

Galcanezumab Beats Placebo for Episodic Migraine

Galcanezumab Beats Placebo for Episodic Migraine

For patients with episodic migraine, galcanezumab is better than placebo for reducing migraine headache days.

Fremanezumab Linked to Fewer Monthly Migraine Days

Fremanezumab Linked to Fewer Monthly Migraine Days

For patients with episodic migraine, fremanezumab is associated with a reduction in the mean number of monthly migraine days.

Fremanezumab effective in preventing episodic migraine

Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.

Galcanezumab Effective in Phase 3 Episodic Cluster Headache Study

Galcanezumab Effective in Phase 3 Episodic Cluster Headache Study

By

The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.

Antidepressant Medications and Headache: Is There a Link?

Antidepressant Medications and Headache: Is There a Link?

By

Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).

Results From Phase 3 Trial of Migraine Tx Ubrogepant Released

Results From Phase 3 Trial of Migraine Tx Ubrogepant Released

By

Allergan announced results from the second Phase 3 trial for their novel acute migraine treatment, ubrogepant.

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

Pain, Psychiatric Comorbidities More Common in Chronic vs Episodic Migraine

By

Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.

New Zolmitriptan Intracutaneous System Safe and Effective for Migraine

New Zolmitriptan Intracutaneous System Safe and Effective for Migraine

By

Researchers conducted a randomized, double-blond, placebo-controlled, dose-ranging trial to assess the use of a new zolmitriptan intracutaneous delivery system in adults with migraine headache.

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

By

Researchers assessed the ability of erenumab to decrease the mean number of acute headache days in patients with episodic migraine.

Comorbidity More Likely With Chronic Migraine vs Episodic Migraine

Comorbidity More Likely With Chronic Migraine vs Episodic Migraine

By

Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

By

Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.

Patient Develops Thunderclap Headaches After Consuming 'Carolina Reaper'

Patient Develops Thunderclap Headaches After Consuming 'Carolina Reaper'

By

The authors note that this appears to be the first case of RCVS secondary to pepper or cayenne ingestion.

Noninvasive Brain Stimulation May Help Prevent Migraines

Noninvasive Brain Stimulation May Help Prevent Migraines

Single-pulse transcranial magnetic stimulation device is safe and easy to use.

Novel Nasal Spray for Migraine Attacks to Be FDA Reviewed

Novel Nasal Spray for Migraine Attacks to Be FDA Reviewed

By

DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.

Sumatriptan Self-Injection System No Longer Available

Sumatriptan Self-Injection System No Longer Available

By

Sumavel DosePro for the treatment of migraine or cluster headache has been discontinued.

Erenumab for Episodic Migraine: A Closer Look at the Data

Erenumab for Episodic Migraine: A Closer Look at the Data

By

For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.

Ubrogepant Effective for Acute Migraine Relief

Ubrogepant Effective for Acute Migraine Relief

By

Allergan has reported positive results from the first of 2 Phase 3 trials for ubrogepant for the treatment of migraine.

GammaCore Approved for Treatment of Acute Migraine Pain

GammaCore Approved for Treatment of Acute Migraine Pain

By

The FDA has granted GammaCore 510(k) expanded clearance to treat migraine related pain.

Sign Up for Free e-newsletters



CME Focus